S&P 500   4,576.79 (+0.85%)
DOW   35,175.08 (+1.72%)
QQQ   383.92 (+0.21%)
AAPL   166.07 (+2.61%)
MSFT   322.95 (-0.02%)
FB   314.67 (+2.55%)
GOOGL   2,841.25 (+0.04%)
AMZN   3,418.54 (+0.85%)
TSLA   979.32 (-3.51%)
NVDA   293.69 (-4.31%)
BABA   120.50 (+7.63%)
NIO   32.04 (-0.34%)
CGC   9.98 (-0.10%)
AMD   136.73 (-5.06%)
GE   96.42 (+3.93%)
MU   81.99 (+0.45%)
T   23.63 (+0.72%)
F   19.29 (+0.78%)
DIS   150.18 (+2.71%)
PFE   52.40 (-3.45%)
AMC   28.97 (-0.14%)
ACB   5.89 (+1.20%)
BA   206.10 (+3.83%)
S&P 500   4,576.79 (+0.85%)
DOW   35,175.08 (+1.72%)
QQQ   383.92 (+0.21%)
AAPL   166.07 (+2.61%)
MSFT   322.95 (-0.02%)
FB   314.67 (+2.55%)
GOOGL   2,841.25 (+0.04%)
AMZN   3,418.54 (+0.85%)
TSLA   979.32 (-3.51%)
NVDA   293.69 (-4.31%)
BABA   120.50 (+7.63%)
NIO   32.04 (-0.34%)
CGC   9.98 (-0.10%)
AMD   136.73 (-5.06%)
GE   96.42 (+3.93%)
MU   81.99 (+0.45%)
T   23.63 (+0.72%)
F   19.29 (+0.78%)
DIS   150.18 (+2.71%)
PFE   52.40 (-3.45%)
AMC   28.97 (-0.14%)
ACB   5.89 (+1.20%)
BA   206.10 (+3.83%)
S&P 500   4,576.79 (+0.85%)
DOW   35,175.08 (+1.72%)
QQQ   383.92 (+0.21%)
AAPL   166.07 (+2.61%)
MSFT   322.95 (-0.02%)
FB   314.67 (+2.55%)
GOOGL   2,841.25 (+0.04%)
AMZN   3,418.54 (+0.85%)
TSLA   979.32 (-3.51%)
NVDA   293.69 (-4.31%)
BABA   120.50 (+7.63%)
NIO   32.04 (-0.34%)
CGC   9.98 (-0.10%)
AMD   136.73 (-5.06%)
GE   96.42 (+3.93%)
MU   81.99 (+0.45%)
T   23.63 (+0.72%)
F   19.29 (+0.78%)
DIS   150.18 (+2.71%)
PFE   52.40 (-3.45%)
AMC   28.97 (-0.14%)
ACB   5.89 (+1.20%)
BA   206.10 (+3.83%)
S&P 500   4,576.79 (+0.85%)
DOW   35,175.08 (+1.72%)
QQQ   383.92 (+0.21%)
AAPL   166.07 (+2.61%)
MSFT   322.95 (-0.02%)
FB   314.67 (+2.55%)
GOOGL   2,841.25 (+0.04%)
AMZN   3,418.54 (+0.85%)
TSLA   979.32 (-3.51%)
NVDA   293.69 (-4.31%)
BABA   120.50 (+7.63%)
NIO   32.04 (-0.34%)
CGC   9.98 (-0.10%)
AMD   136.73 (-5.06%)
GE   96.42 (+3.93%)
MU   81.99 (+0.45%)
T   23.63 (+0.72%)
F   19.29 (+0.78%)
DIS   150.18 (+2.71%)
PFE   52.40 (-3.45%)
AMC   28.97 (-0.14%)
ACB   5.89 (+1.20%)
BA   206.10 (+3.83%)
NASDAQ:TYRA

Tyra Biosciences Stock Forecast, Price & News

$17.91
+0.18 (+1.02%)
(As of 12/6/2021 11:32 AM ET)
Add
Compare
Today's Range
$17.46
$18.40
50-Day Range
$13.46
$31.35
52-Week Range
$12.70
$31.36
Volume
1,714 shs
Average Volume
117,987 shs
Market Capitalization
$739.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive TYRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Tyra Biosciences logo

About Tyra Biosciences

Tyra Biosciences Inc. is a precision oncology company. It focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company's lead product candidate includes TYRA-300. Tyra Biosciences Inc. is based in CARLSBAD, Calif.

Headlines

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $21.00
December 3, 2021 |  americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up to $23.87
November 30, 2021 |  americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.9%
November 29, 2021 |  americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 5%
November 26, 2021 |  americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down to $24.00
November 22, 2021 |  americanbankingnews.com
Tyra Biosciences (NASDAQ:TYRA) Shares Down 9.9%
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TYRA
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$739.15 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/02/2022

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

689th out of 1,388 stocks

Pharmaceutical Preparations Industry

322nd out of 668 stocks

Analyst Opinion: 3.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Tyra Biosciences (NASDAQ:TYRA) Frequently Asked Questions

Is Tyra Biosciences a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Tyra Biosciences stock.
View analyst ratings for Tyra Biosciences
or view top-rated stocks.

When is Tyra Biosciences' next earnings date?

Tyra Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, February 2nd 2022.
View our earnings forecast for Tyra Biosciences
.

How were Tyra Biosciences' earnings last quarter?

Tyra Biosciences Inc (NASDAQ:TYRA) posted its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.72) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.33.
View Tyra Biosciences' earnings history
.

What price target have analysts set for TYRA?

3 brokerages have issued 12-month price objectives for Tyra Biosciences' stock. Their forecasts range from $22.00 to $31.00. On average, they expect Tyra Biosciences' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for Tyra Biosciences
or view top-rated stocks among Wall Street analysts.

When did Tyra Biosciences IPO?

(TYRA) raised $100 million in an IPO on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share.

What is Tyra Biosciences' stock symbol?

Tyra Biosciences trades on the NASDAQ under the ticker symbol "TYRA."

When did the company's quiet period expire?

Tyra Biosciences' quiet period expired on Monday, October 25th. Tyra Biosciences had issued 10,800,000 shares in its public offering on September 15th. The total size of the offering was $172,800,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO were restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Who are Tyra Biosciences' major shareholders?

Tyra Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (17.54%), Boxer Capital LLC (15.32%), BVF Inc. IL (4.11%), Janus Henderson Group PLC (3.33%), Perceptive Advisors LLC (2.39%) and Wellington Management Group LLP (1.69%).

Which institutional investors are buying Tyra Biosciences stock?

TYRA stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Boxer Capital LLC, BVF Inc. IL, Janus Henderson Group PLC, Perceptive Advisors LLC, Wellington Management Group LLP, Deerfield Management Company L.P. Series C, and Jennison Associates LLC.

How do I buy shares of Tyra Biosciences?

Shares of TYRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tyra Biosciences' stock price today?

One share of TYRA stock can currently be purchased for approximately $17.91.

How much money does Tyra Biosciences make?

Tyra Biosciences has a market capitalization of $739.15 million.

How many employees does Tyra Biosciences have?

Tyra Biosciences employs 2,021 workers across the globe.

What is Tyra Biosciences' official website?

The official website for Tyra Biosciences is www.tyra.bio.

Where are Tyra Biosciences' headquarters?

Tyra Biosciences is headquartered at 2656 STATE STREET, CARLSBAD CA, 92008.

How can I contact Tyra Biosciences?

Tyra Biosciences' mailing address is 2656 STATE STREET, CARLSBAD CA, 92008. The company can be reached via phone at 619-728-4760 or via email at [email protected].


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.